US EditionPhase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
- On May 25, 2025, Innovent Biologics announced that the findings from the Phase 3 GLORY-1 trial of mazdutide have been featured in a leading peer-reviewed medical journal, The New England Journal of Medicine.
- The study focused on Chinese adults with overweight or obesity, addressing the limited obesity treatment options and the condition's high mortality burden in China.
- The GLORY-1 trial included 610 individuals with a BMI of 24 kg/m² or higher who had obesity-related health conditions, randomly assigning them to receive either weekly injections of mazdutide at doses of 4 mg or 6 mg, or a placebo, over a period of 48 weeks.
- Mazdutide reduced body weight by 10.97% at week 32 versus 0.24% for placebo , with 37% achieving ≥15% weight loss at week 48, and also improved cardiovascular and metabolic markers.
- The publication marks a milestone for Chinese drug innovation and is expected to impact global obesity guidelines amid rising obesity and the need for tailored, early interventions in China.
32 Articles
32 Articles
Montana Standard
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
SAN FRANCISCO and SUZHOU, China, May 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major…
NEJM Publishes Phase 3 Results of Mazdutide for Obesity Treatment in China
SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of a Phase 3 clinical study of mazdutide , a dual glucagon (GCG)/glucagon-like pep…
Coverage Details
Bias Distribution
- 89% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
